This is a firm fixed-price delivery order awarded to Horizon Therapeutics USA, Inc. by the U.S. Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract is for the supply of KRYSTEXXA (pegloticase), a medication used to treat chronic gout. The delivery order has a ceiling value of $76,896.72 and a completion date of March 4, 2025.
Horizon Therapeutics USA, Inc. is the prime contractor for this award, and there are no specific set-aside designations indicated. The contract is part of a larger $31,375,000 Blanket Purchase Agreement (BPA) held by Horizon with the VA's National Acquisition Center, covering the procurement of several specialty medications to support the VA's healthcare services for veterans. This BPA is established against the GSA Schedule for Pharmaceuticals and Drugs and allows VA medical centers and Veterans Integrated Service Networks (VISNs) to efficiently place orders for Horizon's portfolio of treatments.
Generated 3/1/25, 9:55 AM